ATE433759T1 - Polymerkonjugiertes glycosiliertes neublastin - Google Patents

Polymerkonjugiertes glycosiliertes neublastin

Info

Publication number
ATE433759T1
ATE433759T1 AT07012662T AT07012662T ATE433759T1 AT E433759 T1 ATE433759 T1 AT E433759T1 AT 07012662 T AT07012662 T AT 07012662T AT 07012662 T AT07012662 T AT 07012662T AT E433759 T1 ATE433759 T1 AT E433759T1
Authority
AT
Austria
Prior art keywords
neublastin
polypeptides
glycosilated
conjugated
polymer conjugated
Prior art date
Application number
AT07012662T
Other languages
English (en)
Inventor
Dinah Wen-Yee Sah
Blake R Pepinsky
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33310837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE433759(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE433759T1 publication Critical patent/ATE433759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT07012662T 2003-04-18 2004-04-16 Polymerkonjugiertes glycosiliertes neublastin ATE433759T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46389903P 2003-04-18 2003-04-18

Publications (1)

Publication Number Publication Date
ATE433759T1 true ATE433759T1 (de) 2009-07-15

Family

ID=33310837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07012662T ATE433759T1 (de) 2003-04-18 2004-04-16 Polymerkonjugiertes glycosiliertes neublastin

Country Status (11)

Country Link
US (2) US8163875B2 (de)
EP (3) EP1897552B1 (de)
JP (2) JP4742030B2 (de)
AT (1) ATE433759T1 (de)
AU (1) AU2004233079B2 (de)
CA (2) CA2522364C (de)
DE (1) DE602004021648D1 (de)
DK (1) DK1897552T3 (de)
ES (2) ES2479942T3 (de)
NZ (2) NZ543365A (de)
WO (1) WO2004094592A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783310B2 (ja) 1993-01-28 1998-08-06 トヨタ車体株式会社 エンボス成形方法
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
ES2351215T3 (es) * 2003-01-31 2011-02-01 Biogen Idec Ma Inc. Conjugados poliméricos de neublastina mutada.
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
RU2005138368A (ru) * 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
JP4959566B2 (ja) * 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
EP2335713A3 (de) * 2004-08-19 2011-11-02 Biogen Idec MA Inc. Neublastinvarianten
EP1937295A2 (de) * 2005-10-11 2008-07-02 NS Gene A/S Behandlung von retinopathien mit gfr3-agonisten
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
JP5583005B2 (ja) * 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
HU187037B (en) 1983-04-19 1985-10-28 Tibor Sinko Rope-stretching device
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0585368B1 (de) 1991-04-25 1997-08-06 Brown University Research Foundation Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
ATE275197T1 (de) 1991-09-20 2004-09-15 Amgen Inc Glial neurotrophe faktor
US5939524A (en) 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
EP0802800B1 (de) 1993-08-12 2002-06-12 Neurotech S.A. Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US6063757A (en) 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
EP0943690B1 (de) 1995-12-21 2006-11-29 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
AU736670B2 (en) 1996-09-26 2001-08-02 Medical Research Council Chaperone fragments
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
GB9718908D0 (en) * 1997-09-05 1997-11-12 Rowett Research Services Limit Proteins
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
HK1045528B (zh) 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
EP1175235A1 (de) 1999-04-22 2002-01-30 Eidgenossisch Technische Hochschule Zurich Modifizierte proteinmatrizen
PT1223966E (pt) 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
NZ526610A (en) 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the GDNF ligand family
SK288123B6 (sk) 2001-02-01 2013-09-03 Biogen Idec Ma Inc. Polymer conjugates of neublastin and methods of using same
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002250203B2 (en) * 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
US20040077543A1 (en) 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
EP1389121B1 (de) 2001-04-24 2012-02-22 Purdue Research Foundation Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
US7135334B2 (en) 2001-06-20 2006-11-14 Genentech, Inc. PRO20044 nucleic acids
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US7129085B2 (en) 2001-10-11 2006-10-31 Bristol-Myers Squibb Company Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
JP4310608B2 (ja) 2002-04-25 2009-08-12 東洋紡績株式会社 Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
RU2005138368A (ru) 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
WO2005072764A2 (en) 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
EP1784486B1 (de) 2004-06-23 2011-10-05 TissueGene, Inc. Nervenregeneration
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
EP2335713A3 (de) 2004-08-19 2011-11-02 Biogen Idec MA Inc. Neublastinvarianten
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
EP1937295A2 (de) 2005-10-11 2008-07-02 NS Gene A/S Behandlung von retinopathien mit gfr3-agonisten
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法

Also Published As

Publication number Publication date
AU2004233079A1 (en) 2004-11-04
EP1618179A4 (de) 2008-03-05
US20070238650A1 (en) 2007-10-11
US20120316109A1 (en) 2012-12-13
US8163875B2 (en) 2012-04-24
ES2328640T3 (es) 2009-11-16
NZ543365A (en) 2009-02-28
AU2004233079B2 (en) 2009-09-17
CA2522364A1 (en) 2004-11-04
JP5415392B2 (ja) 2014-02-12
JP2011084567A (ja) 2011-04-28
EP1897552A1 (de) 2008-03-12
DK1897552T3 (da) 2009-10-05
EP1618179A2 (de) 2006-01-25
NZ574121A (en) 2011-06-30
WO2004094592A2 (en) 2004-11-04
JP4742030B2 (ja) 2011-08-10
EP2322205A1 (de) 2011-05-18
CA2522364C (en) 2014-12-09
DE602004021648D1 (de) 2009-07-30
US8642732B2 (en) 2014-02-04
EP1618179B1 (de) 2014-05-07
EP1897552B1 (de) 2009-06-17
ES2479942T3 (es) 2014-07-25
JP2006523709A (ja) 2006-10-19
CA2864810A1 (en) 2004-11-04
WO2004094592A3 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
ATE433759T1 (de) Polymerkonjugiertes glycosiliertes neublastin
EP2298331A3 (de) Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen
PT1288223E (pt) Derivados de peptidos terapeuticos
EA200200017A1 (ru) Терапевтическое средство с ботулиническим нейротоксином
WO2002010195A3 (en) Modified peptides with increased potency
LU93265I2 (fr) Eftrénonacog alfa ou un produit biosimilaire conformément à l'article 10(4) de la directive 2001/83/CE, tel que protégé par le brevet de base
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
IL157446A0 (en) Increased recovery of active proteins
BRPI0417916A (pt) proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
WO2000018921A3 (en) Synthetic peptides having fgf receptor affinity
WO2004069176A3 (en) Polymer conjugates of mutated neublastin
CA2155185A1 (en) Totally synthetic affinity reagents
BR0314092A (pt) proteìnas de fusão de transferrina modificadas
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
AU2002355742A1 (en) Crfr1 selective ligands
MXPA05008168A (es) Conjugados de polimero de neublastina mutada.
DK0382268T3 (da) Aminocarboxylsyrederivater
WO2002016929A3 (en) Urokinase peptide structure mimetics
ES1006455U (es) Elemento de valla.
WO2005078076A3 (en) Tpl2 and its expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties